CODX: Co-Diagnostics, Inc. - Summary | Jitta

Co-Diagnostics, Inc.

NASDAQ:CODX

Price
$3.06
Loss Chance
58.3%
0.01JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
684 / 714
4,129 / 4,228
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (11)
Recent Business Performance (39)
Financial Strength (33)
Return to Shareholders (6)
Competitive Advantage (13)
Jitta Signs
Recent Business PerformanceEarning Growth Last Year
Revenue and EarningEarning loss detected in 2025
Operating MarginDeclined
New Share IssuedMore than 50% in 5 years
SG&A to SalesIncreasing Every Year
Key Stats
Jitta Score
Jitta Line
0.01
100.00%
3.05
158.92%
Health Care Equipment
5.75
6.16%
7.38
31.25%
7.50
8.37%
COMPANY DESCRIPTION
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. The company also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, malaria, dengue, human papillomavirus, chikungunya, and Zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. Co-Diagnostics, Inc. was incorporated in 2013 and is based in Salt Lake City, Utah.